ArtiBest for Knee Osteoarthritis

Recruiting now · Not applicable

Conditions studied: Knee Osteoarthristis

In brief

The goal of this clinical trial is to evaluate the real-world effectiveness and safety of ArtiBest in the treatment of knee osteoarthritis. The main questions it aims to answer are: 1. The change from baseline The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 26 weeks post injection. 2. The change from baseline VAS resting pain score at 12 and 26 weeks post injection. 3. The change from baseline The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 12 weeks post injection. 4. The change from baseline Patient's Global Assessment PGA) using VAS scoring at 12 and 26 weeks post injection. 5. The OMERACT OARSI responder rate at 12 and 26 weeks post injection. 6. The VAS satisfaction score at 12 and 26 weeks post injection 7. The incidence of Adverse events reported during the study period. Participants will undergo a single injection of ArtiBest at treatment visit, and three follow up visits at week 4 , 12 , and 26.

Key facts

Study ID

NCT06994546

Run by

Maxigen Biotech Inc.

People needed

60

Starts

2025-03-11

Expected to finish

2026-04-30

Last updated by the study team

2025-05-29

Who can join

Age: 35 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age from 35 to 85 years.
• Subject with x ray imaging evidence of knee OA as Kellgren Lawrence grade = 2 or 3 within 1 month at screening.
• Subject diagnosed with mild to moderate knee OA, particularly in patients who failed to respond adequately to conservative nonpharmacologic therapies or analgesics.
• Subject with a 100 mm VAS resting pain score ≥ 30 mm in the studied knee at both the screening and treatment visit (screening visit and treatment visit can be on the same day)
• Able and willing to comply with all study visits and procedures.
• Willin g and capable of providing written informed consent.

You may not qualify if…

• Subjects with known hypersensitivity to hyaluronate.
• Subjects with infections or skin diseases in the area of the injection site.
• Pregnancy or breast feeding woman.
• Joining other interventional trial s within 3 months prior to injecting this study product
• Subject receive an intra articular (IA) injection of Hyaluronic Acid (HA) and/or steroid in target knee within 6 months prior to the trial
• Subjects with rheumatoid arthritis
• Any surgery to the target knee within the 12 months prior to the trial, or surgery to the contralateral knee or other weight bearing joint if it will interfere with knee assessments

Where it is running

• Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.